A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
At a glance
- Drugs MERS monoclonal antibody (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions
- 10 Jan 2018 According to an SAB Biotherapeutics media release, John H. Beigel is the principal investigator of this trial.
- 10 Jan 2018 According to an SAB Biotherapeutics media release, results from this trial have been published in The Lancet Infectious Diseases.
- 09 May 2017 Planned primary completion date changed from 30 Apr 2017 to 10 Apr 2018.